{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:35Z","timestamp":1790963615993,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Effective available treatment options for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who relapse after becoming refractory to both a covalent Bruton Tyrosine Kinase inhibitor (cBTKi) and a B cell leukemia\/lymphoma 2 inhibitor (BCL2i) remain limited, and prognosis is very poor. Emerging areas of drug development include cellular therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies. However, cost, accessibility, toxicity, and the need for either prolonged or repeated hospitalization prevent universal application of these therapies. Given this area of unmet clinical need, we present this review article on Bruton Tyrosine Kinase (BTK) degraders in patients with CLL\/SLL. We focus on their development as a drug class, the up-to-date clinical data available, as well as future directions. BTK protein degraders are a novel drug class with an alternate mechanism of action (MOA), compared to cBTKis and non-covalent BTKis (ncBTKis), causing ubiquitination of BTK, thereby leading to its degradation through the proteasome. Encouraging pre-clinical data show that this MOA allows BTK protein degraders to overcome common BTK mutations. We focus on four agents which are under investigation in B-cell malignancies in early clinical trials: BGB-16673, NX-2127, NX-5948, and AC676. Preliminary data suggest a comparable safety and toxicity profile between agents across this drug class with many patients on phase 1 trials deriving durable clinical benefit. Optimal sequencing of BTK degraders in the therapeutic landscape of CLL\/SLL treatment is yet to be established. Further trials investigating these agents in combination with other targeted CLL agents may help to further understand their applicability. An effective, tolerable oral class of drugs would be invaluable in the treatment of patients with multiply relapsed CLL\/SLL.<\/jats:p>","DOI":"10.3390\/cancers17030557","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T11:32:32Z","timestamp":1738841552000},"page":"557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-5503","authenticated-orcid":false,"given":"Ross T.","family":"Salvaris","sequence":"first","affiliation":[{"name":"Department of Hematology, Monash Health, Clayton, VIC 3168, Australia"},{"name":"School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Brennan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5877","authenticated-orcid":false,"given":"Katharine L.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia"},{"name":"School of Medicine, University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","volume":"144","author":"Robrecht","year":"2024","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/cncr.30549","article-title":"Improving access to high-cost cancer drugs in Latin America: Much to be done","volume":"123","author":"Ruiz","year":"2017","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2023-174603","article-title":"Outcomes of Venetoclax Retreatment After MRD-Guided Venetoclax +\/\u2212 Ibrutinib: Results of the Improve Study","volume":"142","author":"Albi","year":"2023","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/ajh.26682","article-title":"Approach to a patient with \u201cdouble refractory\u201d chronic lymphocytic leukemia: \u201cDouble, double toil and trouble\u201d (Shakespeare)","volume":"97","author":"Aronson","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2023-185852","article-title":"Pirtobrutinib in Post-cBTKi CLL\/SLL: ~30 Months Follow-up and Subgroup Analysis With\/Without Prior BCL2i from the Phase 1\/2 BRUIN Study","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e7809236","DOI":"10.1097\/01.HS9.0000969416.78092.36","article-title":"P628 Updated analysis of Bellwave-001: A phase 1\/2 open-label dose-expansion study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies","volume":"7","author":"Woyach","year":"2023","journal-title":"Hemasphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transpl. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","unstructured":"Sava, J. (2024, November 19). FDA Approves Liso-Cel in Relapsed or Refractory CLL\/SLL. Available online: https:\/\/www.targetedonc.com\/view\/fda-approves-liso-cel-in-relapsed-or-refractory-cll-sll#:~:text=Lisocabtagene%20maraleucel%20(liso%2Dcel%3B,lymphoma%202%20inhibitor%20(BCL2i)."},{"key":"ref_19","unstructured":"Fakhri, B. (2024). Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1. 66th ASH Annual Meeting Abstracts, Proceedings of the 66th ASH Annual Meeting and Exposition, San Diego, CA, USA, 7\u201310 December 2024, American Society of Haematology."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2023-180143","article-title":"Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: Potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp\u2014A Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"P5-04-18","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Neklesa, T., Snyder, L.B., Willard, R.R., Vitale, N., Pizzano, J., Gordon, D.A., Bookbinder, M., Macaluso, J., Dong, H., and Ferraro, C. (2019, January 14\u201316). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. Proceedings of the 2019 Genitourinary Cancers Symposium, San Francisco, CA, USA.","DOI":"10.1200\/JCO.2019.37.7_suppl.259"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110446","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: A graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell Signal"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-319-91439-8_4","article-title":"Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor","volume":"212","author":"Isfort","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/jm500305p","article-title":"Structure-based drug design of RN486, a potent and selective Bruton\u2019s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis","volume":"58","author":"Lou","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: A safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton\u2019s Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed\/Refractory B Cell Malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"ref_42","unstructured":"Linton, K., Collins, G., Forconi, F., Shah, N., Dixit, K., Munir, T., Omer, Z., El-Sharkawi, D., Doorduijn, J., and Alencar, A.J. (2024, November 11). Latest Results from an Ongoing First-in-Human Phase 1A\/B Study of NX-5948, a Selective Bruton\u2019s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed\/Refractory CLL and Other B-Cell Malignancies. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422259\/kim.linton.latest.results.from.an.ongoing.first-in-human.phase.1a.b.study.of.html?f=menu%3D6*browseby%3D8*sortby%3D2*ce_id%3D2552*ot_id%3D29194*marker%3D5099*featured%3D18498."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton\u2019s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"ref_44","unstructured":"Parrondo, R., Thompson, M., Frustaci, A., Allan, J., Ghia, P., Vinogradov, I., Tam, C.S., Trotman, J., Choi, M., and Chen, X. (2024, October 11). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients with Relapsed or Refractory (R\/R) CLL\/SLL: Results from the Phase 1 BGB-16673-101 Study. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422261\/ricardo.parrondo.preliminary.efficacy.and.safety.of.the.bruton.tyrosine.kinase.html?f=menu%3D6*browseby%3D8*sortby%3D2*ce_id%3D2552*ot_id%3D29194*marker%3D5099*featured%3D18498."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and Safety of the Bruton\u2019s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a\/b Study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4422.1","DOI":"10.1182\/blood-2024-194009","article-title":"A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e24358c2","DOI":"10.1097\/01.HS9.0000971772.24358.c2","article-title":"P1219: BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models","volume":"7","author":"Wang","year":"2023","journal-title":"Hemasphere"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mares, A., Miah, A.H., Smith, I.E.D., Rackham, M., Thawani, A.R., Cryan, J., Haile, P.A., Votta, B.J., Beal, A.M., and Capriotti, C. (2020). Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-0868-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First Results from a Phase 1, First-in-Human Study of the Bruton\u2019s Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R\/R) B-Cell Malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_52","unstructured":"Cheah, C.Y., Seymour, J.F., Lasica, M., Eradat, H., Frustaci, A., Allan, J., Lin, V., Trotman, J., Advani, R., and Chen, X. (2024, November 13). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients with Relapsed or Refractory (R\/R) Indolent NHL: Results from the Phase 1 BGB-16673-101 Study. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419206\/chan.cheah.preliminary.efficacy.and.safety.of.the.bruton.tyrosine.kinase.28btk29.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29170%2Amarker%3D5101%2Afeatured%3D18527."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1182\/blood-2022-168483","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors","volume":"140","author":"Fiskus","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"ref_55","unstructured":"Flaherty, C. (2024, November 11). FDA Grants Fast Track Status to NX-5948 for Relapsed\/Refractory CLL\/SLL. Available online: https:\/\/www.onclive.com\/view\/fda-grants-fast-track-status-to-nx-5948-for-relapsed-refractory-cll-sll."},{"key":"ref_56","unstructured":"Seymour, C. (2024, November 11). FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL\/SLL. Available online: https:\/\/www.onclive.com\/view\/fda-grants-fast-track-designation-to-bgb-16673-in-previously-treated-cll-sll."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:28:17Z","timestamp":1760027297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030557"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030557","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}